Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Alexanian

Showing results (31-40 of 196) with videos related to

Pageof 20
Sort By:
Blood|October 1, 1982
Myeloma protein kinetics following chemotherapyP McLaughlin, R Alexanian
European Journal of Haematology. Supplementum|January 1, 1989
Prognostic factors in multiple myeloma: the M.D. Anderson experienceB Barlogie, R Alexanian
Annals of Internal Medicine|May 1, 1979
Solid tumors in multiple myelomaR Stegman, R Alexanian
Postgraduate Medicine|May 1, 1974
Multiple myeloma and macroglobulinemia. Advances in treatmentV G Ruiz, R Alexanian
American Journal of Hematology|June 1, 1992
Irreversibility of drug resistance in VAD-refractory myelomaM A Dimopoulos, R Alexanian
Cancer|August 1, 1976
Erythrokinetics and androgens in bone marrow cancerR Alexanian, C P Alfrey
Medical Oncology (Northwood, London, England)|April 28, 2022
Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growthArshak R Alexanian, Avonlea Brannon
The Journal of Laboratory and Clinical Medicine|February 1, 1970
Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapyR Alexanian, P J Migliore
Annals of Internal Medicine|April 1, 1976
Multiple myeloma in young personsG M Hewell, R Alexanian
Blood|March 15, 1994
Waldenstrom's macroglobulinemiaM A Dimopoulos, R Alexanian
Pageof 20

Showing results (31-40 of 196) with videos related to

Sort By:
Pageof 20
Blood|October 1, 1982
Myeloma protein kinetics following chemotherapyP McLaughlin, R Alexanian
European Journal of Haematology. Supplementum|January 1, 1989
Prognostic factors in multiple myeloma: the M.D. Anderson experienceB Barlogie, R Alexanian
Annals of Internal Medicine|May 1, 1979
Solid tumors in multiple myelomaR Stegman, R Alexanian
Postgraduate Medicine|May 1, 1974
Multiple myeloma and macroglobulinemia. Advances in treatmentV G Ruiz, R Alexanian
American Journal of Hematology|June 1, 1992
Irreversibility of drug resistance in VAD-refractory myelomaM A Dimopoulos, R Alexanian
Cancer|August 1, 1976
Erythrokinetics and androgens in bone marrow cancerR Alexanian, C P Alfrey
Medical Oncology (Northwood, London, England)|April 28, 2022
Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growthArshak R Alexanian, Avonlea Brannon
The Journal of Laboratory and Clinical Medicine|February 1, 1970
Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapyR Alexanian, P J Migliore
Annals of Internal Medicine|April 1, 1976
Multiple myeloma in young personsG M Hewell, R Alexanian
Blood|March 15, 1994
Waldenstrom's macroglobulinemiaM A Dimopoulos, R Alexanian
Pageof 20